

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

DENA A. GILMORE, On Behalf of Herself and All
Others Similarly Situated,

Plaintiff,

v.

MARK J. FOLEY,

Defendant.

C.A. No. 2025-1415-NAC

SEANE JONES, on behalf of himself and similarly
situated stockholders,

Plaintiff,

v.

MARK J. FOLEY,

Defendant.

C.A. No. 2026-0177-NAC

PROOF OF CLAIM AND RELEASE

I. GENERAL INSTRUCTIONS

1. You are a Class Member if you are a former holder, whether beneficial or of record (including as necessary for relief the legal representatives, heirs, successors-in-interest, transferees, and assignees of such holders) of Revance Therapeutics, Inc. ("Revance") common stock as of the February 6, 2025 closing of the merger between Revance and Crown Laboratories, Inc. ("Crown") (the "Merger") who (i) received \$3.65 per share in cash in exchange for their shares of Revance common stock ("Merger Consideration") (on February 6, 2025), and (ii) acquired your shares either (a) prior to February 29, 2024, or (b) between February 29, 2024 and February 6, 2025, but will not receive compensation as to those shares pursuant to the settlement in the consolidated securities class action styled *In re Revance Therapeutics, Inc. Securities Litigation*, Case No. 3:25-cv-0018-EJR (M.D. Tenn.) (the "Securities Action" and the "Securities Action Settlement"). To recover as a Class Member based on your claims in the above-captioned actions entitled *Dena A. Gilmore v. Mark J. Foley*, C.A. No. 2025-1415 and *Seane Jones v. Mark J. Foley*, C.A. No. 2026-0177 (the "Litigation" or "Actions"), you must complete and, on page 3 hereof, sign this Proof of Claim and Release. If you fail to submit a properly addressed (as set forth in paragraph 3 below) Proof of Claim and Release, postmarked or received by the date shown below, your claim may be rejected and you may be precluded from any recovery from the Net Settlement Fund created in connection with the proposed Settlement of the Litigation.

2. Submission of this Proof of Claim and Release, however, does not assure that you will share in the proceeds of the Settlement.

3. YOU MUST MAIL OR SUBMIT ONLINE YOUR COMPLETED AND SIGNED PROOF OF CLAIM AND RELEASE, ACCOMPANIED BY COPIES OF THE DOCUMENTS REQUESTED HEREIN IF READILY AVAILABLE, NO LATER THAN MARCH 17, 2017 TO THE COURT-APPOINTED SETTLEMENT ADMINISTRATOR IN THIS CASE, AT THE FOLLOWING ADDRESS:

Revance Therapeutics Merger Stockholder Litigation
RG/2 Claims Administration LLC
P.O. Box 59479
Philadelphia, PA 19102-9479
Toll-Free: (866) 742-4955
Facsimile: (215) 827-5551
Email: info@rg2claims.com

Online Submissions: www.rg2claims.com/revance.html

If you are NOT a Member of the Class (as defined in the Notice of Pendency and Proposed Settlement of Class Actions (the “Notice”)), DO NOT submit a Proof of Claim and Release.

4. If you are a Class Member, you will be bound by the terms of any judgment entered in the Litigation, including the releases provided therein, **WHETHER OR NOT YOU SUBMIT A PROOF OF CLAIM AND RELEASE.**

II. CLAIM FORM

Pursuant to the proposed Plan of Allocation, Class Members who submit a valid Proof of Claim to the Settlement Administrator may share in the recovery, *pro rata* with their stock holdings (the proposed “Plan of Allocation”). Your actual recovery will be a proportion of the Net Settlement Fund determined by your claim as compared to the total claims of all eligible Class Members who submit acceptable Proofs of Claim.

Please complete the entire form below. Use this form to state the number of shares of Revance common stock that you held at the closing of the Merger (on February 6, 2025), and (ii) acquired either (a) prior to February 29, 2024, or (b) between February 29, 2024 and February 6, 2025, and which were cashed out for \$3.65 per share. If readily available, please provide copies of broker confirmations or other documentation, such as trade confirmations or screen shots, of your holdings in Revance stock, as attachments to your claim. If any such documents are not in your possession, please obtain a copy or equivalent documents from your broker because these documents are helpful to prove and expedite processing your claim. Failure to provide this documentation could delay verification of your claim or result in rejection of your claim.

PROOF OF CLAIM AND RELEASE

Must Be Postmarked or Received No Later Than: March 17, 2027

PART I: CLAIMANT IDENTIFICATION

Name:		
Address 1:		
Address 2:		
City:	State:	ZIP:
Foreign Province:	Foreign Country:	
Day Phone:	Evening Phone:	
Email Address:		
Claimant Type: (Individual, Joint, Corporation, etc.) _____		
Record Owner's Name: (If different from beneficial owner listed above)		
Social Security Number: (for individuals)	OR	Taxpayer Identification Number: (for estates, trusts, corporations, etc.)

PART II: SCHEDULE OF TRANSACTIONS IN REVANCE COMMON STOCK

1. HOLDINGS AS OF FEBRUARY 29, 2024 – State the total number of shares of Revance common stock held as of the opening of trading on February 29, 2024. If none, write “zero” or “0.” (Must be documented.)			
2. PURCHASES/ACQUISITIONS BETWEEN FEBRUARY 29, 2024 AND FEBRUARY 6, 2025 – Separately list every purchase/acquisition of Revance common stock from after the opening of trading on February 29, 2024 through and including the close of trading on February 6, 2025. (Must be documented.)			
Date of Purchase/Acquisition (Chronologically) (Month/ Day/Year)	Number of Shares Purchased	Purchase/Acquisition Price Per Share	Total Purchase/Acquisition Price (excluding taxes, commissions, and fees)
/ /		\$	\$
/ /		\$	\$
/ /		\$	\$
/ /		\$	\$
/ /		\$	\$
3. SALES BETWEEN FEBRUARY 29, 2024 AND FEBRUARY 6, 2025 – Separately list each sale/disposition of Revance common stock from after the opening of trading on February 29, 2024 through and including the close of trading on February 6, 2025. (Must be documented.)			
Date of Sale (Chronologically) (Month/Day/Year)	Number of Shares Sold	Sale Price Per Share	Total Sale Price (excluding taxes, commissions, and fees)
/ /		\$	\$
/ /		\$	\$
/ /		\$	\$
/ /		\$	\$
/ /		\$	\$
4. END HOLDINGS – State the total number of shares of publicly-traded Revance common stock held as of the close of the Merger on February 6, 2025 that were exchanged for \$3.65 per share in connection with the closing of the Merger. If none, write “zero” or “0.” (Must be documented.)			

PART III: SECURITIES ACTION SETTLEMENT QUESTIONS

1. Did you submit any claims related to your Revance holdings in connection with the Securities Action or Securities Action Settlement? ☐ Yes ☐ No. **IF YES, provide a copy of that claim form.**
2. Have you received any payments in connection with any claim submitted in connection with the Securities Action or Securities Action Settlement? ☐ Yes ☐ No. **IF YES, how much was the payment?** _____

YOUR SIGNATURE BELOW WILL CONSTITUTE YOUR ACKNOWLEDGMENT OF THE RELEASE DESCRIBED IN THE NOTICE ISSUED WITH THIS PROOF OF CLAIM FORM.

SUBMISSION TO JURISDICTION OF COURT AND ACKNOWLEDGMENTS

I (We) submit this Proof of Claim and Release under the terms of the Stipulation of Settlement described in the Notice. I (We) also submit to the jurisdiction of the Court of Chancery of the State of Delaware with respect to my (our) claim as a Class Member and for purposes of enforcing the release set forth herein. I (We) further acknowledge that I am (we are) bound by and subject to the terms of any judgment that may be entered in the Litigation. I (We) agree to furnish additional information to the Settlement Administrator to support this claim if requested to do so. I (We) have not submitted any other claim in connection with my (our) holding of Revance common stock as of the closing of the Merger (on February 6, 2025), unless stated otherwise above regarding the Securities Action Settlement.

I (We) hereby warrant and represent that I (we) have not assigned or transferred or purported to assign or transfer, voluntarily or involuntarily, any claim or matter released pursuant to this release or any other part or portion thereof.

I (We) hereby warrant and represent that I (we) have included information (including supporting documentation if readily available) about the number of shares of Revance stock held by me (us) as of the closing of the Merger (on February 6, 2025).

I (We) hereby warrant and represent that I (we) held Revance shares as of the closing of the Merger (on February 6, 2025); that I (we) had my (our) shares exchanged for \$3.65 per share in connection with the closing of the Merger; that I (we) acquired said shares either (a) prior to February 29, 2024, or (b) between February 29, 2024 and February 6, 2025, and that I am not to the best of my knowledge eligible to receive and I have not received compensation as to those shares pursuant to the Securities Action Settlement.

I (We) hereby warrant and represent that I am (we are) not a Defendant or other person excluded from the Class.

I declare under penalty of perjury under the laws of the United States of America that the foregoing information supplied by the undersigned is true and correct.

Executed this _____ day of _____ (Month/Year)

in _____
(City) (State/Country)

(Sign your name here)

(Type or print your name here)

(Capacity of person(s) signing, e.g., Beneficial Purchaser or Acquirer, Executor or Administrator)

Revance Therapeutics Merger Stockholder Litigation
RG/2 Claims Administration LLC
P.O. Box 59479
Philadelphia, PA 19102-9479

Reminder Checklist:

1. Please sign the above release and declaration.
2. Remember to attach copies of supporting documentation, if readily available.
3. Do not send originals of stock certificates or other documentation as they will not be returned.
4. Keep a copy of your Proof of Claim and Release and all supporting documentation for your records.
5. If you desire an acknowledgment of receipt of your Proof of Claim and Release, please send it Certified Mail, Return Receipt Requested.
6. If you move, please send your new address to the address below.
7. Do not use red pen or highlighter on the Proof of Claim and Release or supporting documentation.

THIS PROOF OF CLAIM AND RELEASE MUST BE SUBMITTED ONLINE AT www.rg2claims.com/revance.html
BY MARCH 17, 2027 OR, IF MAILED, POSTMARKED NO LATER THAN MARCH 17, 2027, ADDRESSED AS
FOLLOWS:

Revance Therapeutics Merger Stockholder Litigation
RG/2 Claims Administration LLC
P.O. Box 59479
Philadelphia, PA 19102-9479
Toll-Free: (866) 742-4955
Facsimile: (215) 827-5551
Email: info@rg2claims.com

Online Submissions: www.rg2claims.com/revance.html